EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients


Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients



Journal of Clinical Gastroenterology 36(1): 41-43



ISSN/ISBN: 0192-0790

PMID: 12488707

DOI: 10.1097/00004836-200301000-00013

Saccharomyces cerevisiae is widely used as a probiotic compound. Clinical data suggest that this agent is safe and effective. We report two cases of fungemia caused by S. cerevisiae occurring in immunosuppressed patients treated orally with S. boulardii Molecular typing confirmed clonality in isolate strains from patients and the capsule. Physicians caring for immunosuppressed patients must be aware of this potential serious complication of probiotic use.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047300192

Download citation: RISBibTeXText

Related references

Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. Journal of Infection 54(3): 310-311, 2007

Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Medicine 26(6): 825, 2000

Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. American Journal of Medicine 105(1): 71-72, 1998

Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Medical Mycology Case Reports 15: 33-35, 2017

Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 40(11): 1635-1637, 2005

Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 8(6): 504-505, 2000

Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 64(12): 1521-1526, 2021

Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. Medical Mycology Case Reports 18: 15-17, 2017

Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. Revista Argentina de Microbiologia 52(1): 27-30, 2020

Saccharomyces cerevisiae boulardii transient fungemia after intravenous self-inoculation. Medical Mycology Case Reports 2: 63-64, 2013

Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration. Infectious Diseases now 51(3): 293-295, 2021

Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 28(4): 930, 2000

Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. Journal of Clinical Microbiology 41(11): 5340-5343, 2003

Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 38(3-4): 119-123, 1995

Saccharomyces boulardii fungemia caused by treatment with a probioticum. Bmj Case Reports 2012, 2012